The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still’s disease

References

• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81:194–200.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Le Moel G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28:322–329.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Kawaguchi Y, Tada Y, et al. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still’s disease: a multicenter retrospective study. Mod Rheumatol. 2018;28:858–864.
   PubMed Web of Science ®Google Scholar
• Fardet L, Coppo P, Kettaneh A, et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 2008;58:1521–1527.
   PubMed Web of Science ®Google Scholar
• Vignes S, Le Moel G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis. 2000;59:347–350.
   PubMed Web of Science ®Google Scholar
• Jeon YK, Paik JH, Park SS, et al. Spectrum of lymph node pathology in adult onset Still’s disease; analysis of 12 patients with one follow up biopsy. J Clin Pathol. 2004;57:1052–1056.
   PubMed Web of Science ®Google Scholar
• Zhao DB, Dai SM, Liu XP, et al. Interstitial inflammation in visceral organs is a pathologic feature of adult-onset Still’s disease. Rheumatol Int. 2011;31:923–927.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Kubota K, Takahashi Y, et al. Clinical value of (1)(8)F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still’s disease: a seven-case series and review of the literature. Mod Rheumatol. 2014;24:645–650.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14:965–976.
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. Joint Bone Spine. 2018;85:285–293.
   PubMed Web of Science ®Google Scholar
• Wouters JM, van der Veen J, van de Putte LB, et al. Adult onset Still’s disease and viral infections. Ann Rheum Dis. 1988;47:764–767.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Esdaile JM, Decary F, et al. HLA-Bw35 and prognosis in adult Still’s disease. Arthritis Rheum. 1981;24:1469–1472.
   PubMedGoogle Scholar
• Wouters JM, Reekers P, van de Putte LB, et al. Adult-onset Still’s disease. Disease course and HLA associations. Arthritis Rheum. 1986;29:415–418.
   PubMed Web of Science ®Google Scholar
• Joung CI, Lee HS, Lee SW, et al. Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol. 2003;21:489–492.
   PubMed Web of Science ®Google Scholar
• Jung JY, Choi B, Sayeed HM, et al. Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease. Int J Immunopathol Pharmacol. 2018;32:2058738418791284.
   Web of Science ®Google Scholar
• Sugiura T, Maeno N, Kawaguchi Y, et al. A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther. 2006;8:R60.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376.
   PubMed Web of Science ®Google Scholar
• Wang FF, Huang XF, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther. 2013;15:R65.
   PubMed Web of Science ®Google Scholar
• Perez C, Artola V. Adult Still’s disease associated with mycoplasma pneumoniae infection. Clin Infect Dis. 2001;32:E105–106.
   PubMed Web of Science ®Google Scholar
• Brown RA, Henderlight M, Do T, et al. Neutrophils from children with systemic juvenile idiopathic arthritis exhibit persistent proinflammatory activation despite long-standing clinically inactive disease. Front Immunol. 2018;9:2995.
   PubMed Web of Science ®Google Scholar
• Komiya A, Matsui T, Nogi S, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol. 2012;41:156–158.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50:1286–1295.
   PubMed Web of Science ®Google Scholar
• Hu Q, Shi H, Zeng T, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:9.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Rago C, Breda L, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol. 2017;36:2839–2845.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol. 2017;13:1041–1047.
   PubMed Web of Science ®Google Scholar
• Junge G, Mason J, Feist E. Adult onset Still’s disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47:295–302.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–1486.
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–2427.
   PubMed Web of Science ®Google Scholar
• Priori R, Barone F, Alessandri C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50:776–780.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–2198.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA, Chapira E, Fernandes ML, et al. Interleukin 6: a possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol. 1996;14:653–655.
   PubMed Web of Science ®Google Scholar
• Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99:3505–3516.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis. 2004;63:1300–1306.
   PubMed Web of Science ®Google Scholar
• Raziuddin S, Bahabri S, Al-Dalaan A, et al. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Immunopathol. 1998;86:192–198.
   PubMedGoogle Scholar
• Omoyinmi E, Hamaoui R, Pesenacker A, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2012;51:1881–1886.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Fall N, Harley JB, et al. Monocyte MicroRNA expression in active systemic juvenile idiopathic arthritis implicates MicroRNA-125a-5p in polarized monocyte phenotypes. Arthritis Rheumatol. 2016;68:2300–2313.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Chen HH, et al. The associations of circulating CD4+CD25high regulatory T cells and TGF-beta with disease activity and clinical course in patients with adult-onset Still’s disease. Connect Tissue Res. 2010;51:370–377.
   PubMed Web of Science ®Google Scholar
• Chi H, Liu D, Sun Y, et al. Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity. Arthritis Res Ther. 2018;20:54.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Kishida D, Ueno KI, et al. Characteristics of circulating natural killer cells and their interferon-gamma production in active adult-onset Still’s disease. J Rheumatol. 2019 epub
   PubMedGoogle Scholar
• Park JH, Kim HS, Lee JS, et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still’s disease. J Rheumatol. 2012;39:2000–2007.
   PubMed Web of Science ®Google Scholar
• Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18:e27.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, Adjemian S, Branco LM, et al. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Chavan SS, et al. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol Med. 2015;21(Suppl 1):S6–s12.
   PubMedGoogle Scholar
• Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol. 2017;14:43–64.
   PubMed Web of Science ®Google Scholar
• Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40–48.
   PubMed Web of Science ®Google Scholar
• Bobek D, Grcevic D, Kovacic N, et al. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J. 2014;12:50.
   PubMed Web of Science ®Google Scholar
• Schierbeck H, Pullerits R, Pruunsild C, et al. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol. 2013;40:1604–1613.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH, Sohn S, et al. Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash. Clin Rheumatol. 2016;35:1937–1942.
   PubMed Web of Science ®Google Scholar
• Maillard-Lefebvre H, Boulanger E, Daroux M, et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009;48:1190–1196.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Khan H, Siddiqui Z, et al. AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin Cancer Biol. 2018;49:44–55.
   PubMed Web of Science ®Google Scholar
• Di Pino A, Urbano F, Zagami RM, et al. Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes. J Clin Endocrinol Metab. 2016;101:1701–1709.
   PubMed Web of Science ®Google Scholar
• Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb J. 2008;22:3716–3727.
   PubMed Web of Science ®Google Scholar
• Pullerits R, Bokarewa M, Dahlberg L, et al. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:R817–824.
   PubMed Web of Science ®Google Scholar
• Myles A, Viswanath V, Singh YP, et al. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol. 2011;38:1994–1999.
   PubMed Web of Science ®Google Scholar
• Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147:229–241.
   PubMed Web of Science ®Google Scholar
• Holzinger D, Foell D, Kessel C. The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Mol Cell Pediatr. 2018;5:7.
   PubMedGoogle Scholar
• Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628–637.
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, Haas PJ, Frosch M, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis. 2003;62:236–241.
   PubMed Web of Science ®Google Scholar
• Kim HA, An JM, Nam JY, et al. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2012;39:1399–1406.
   PubMed Web of Science ®Google Scholar
• Kim HA, Han JH, Kim WJ, et al. TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still’s disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17081342.
   Google Scholar
• Jung SY, Park YB, Ha YJ, et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol. 2010;37:1029–1034.
   PubMed Web of Science ®Google Scholar
• Guo Q, Zha X, Li C, et al. Serum calprotectin–a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35:73–79.
   PubMed Web of Science ®Google Scholar
• Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58:3924–3931.
   PubMed Web of Science ®Google Scholar
• Bae CB, Suh CH, An JM, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2014;41:2403–2408.
   PubMed Web of Science ®Google Scholar
• Moller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72:1–13.
   PubMed Web of Science ®Google Scholar
• Cairo G, Recalcati S, Mantovani A, et al. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32:241–247.
   PubMed Web of Science ®Google Scholar
• Gaini S, Pedersen SS, Koldkaer OG, et al. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol. 2008;151:423–431.
   PubMed Web of Science ®Google Scholar
• Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6–10.
   PubMed Web of Science ®Google Scholar
• Sakumura N, Shimizu M, Mizuta M, et al. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;10:459–465.
   Google Scholar
• Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–971.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177–183.
   PubMed Web of Science ®Google Scholar
• Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398–1407.
   PubMed Web of Science ®Google Scholar
• de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–598.
   PubMed Web of Science ®Google Scholar
• Zou YQ, Lu LJ, Li SJ, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still’s disease. Clin Biochem. 2008;41:519–524.
   PubMed Web of Science ®Google Scholar
• Becker H, Gaubitz M, Domschke W, et al. Potential role of macrophage migration inhibitory factor in adult-onset Still’s disease. Scand J Rheumatol. 2009;38:69–71.
   PubMed Web of Science ®Google Scholar
• Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med. 2017;23:279–287.
   PubMed Web of Science ®Google Scholar
• Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2017;16:1160–1173.
   PubMed Web of Science ®Google Scholar
• Giaglis S, Hahn S, Hasler P. “The NET outcome”: are neutrophil extracellular traps of any relevance to the pathophysiology of autoimmune disorders in childhood? Front Pediatr. 2016;4:97.
   PubMed Web of Science ®Google Scholar
• Hu X, Xie Q, Mo X, et al. The role of extracellular histones in systemic-onset juvenile idiopathic arthritis. Ital J Pediatr. 2019;45:14.
   PubMed Web of Science ®Google Scholar
• Skendros P, Chrysanthopoulou A, Rousset F, et al. Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1beta-mediated familial mediterranean fever attack through autophagy-driven neutrophil extracellular traps. J Allergy Clin Immunol. 2017;140:1378–1387.e1313.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum. 2005;53:320–327.
   PubMed Web of Science ®Google Scholar
• Bloom BJ, Nelson SM, Eisenberg D, et al. Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis. J Rheumatol. 2005;32:366–372.
   PubMed Web of Science ®Google Scholar
• Gouwy M, De Buck M, Portner N, et al. Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur J Immunol. 2015;45:101–112.
   PubMed Web of Science ®Google Scholar
• De Buck M, Berghmans N, Portner N, et al. Serum amyloid A1alpha induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils. J Leukoc Biol. 2015;98:1049–1060.
   PubMed Web of Science ®Google Scholar
• Migita K, Izumi Y, Jiuchi Y, et al. Serum amyloid A induces NLRP-3-mediated IL-1beta secretion in neutrophils. PLoS One. 2014;9:e96703.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Giani T, Fioravanti A, et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J. 2012;53:1045–1048.
   PubMed Web of Science ®Google Scholar
• Yashiro M, Furukawa H, Asano T, et al. Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still’s disease. Medicine (Baltimore). 2018;97:e13394.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   PubMed Web of Science ®Google Scholar
• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004;50:1709–1720.
   PubMed Web of Science ®Google Scholar
• Gohar F, Anink J, Moncrieffe H, et al. S100A12 is associated with response to therapy in juvenile idiopathic arthritis. J Rheumatol. 2018;45:547–554.
   PubMed Web of Science ®Google Scholar
• Senda N, Miyagaki T, Kamijo H, et al. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma. Eur J Dermatol. 2018;28:621–627.
   PubMed Web of Science ®Google Scholar
• Mihm S. Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver. Int J Mol Sci. 2018;19103104.
   PubMed Web of Science ®Google Scholar
• Hernandez C, Huebener P, Pradere JP, et al. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest. 2018;128:2436–2451.
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–1109.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lin CC, et al. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease. BMC Musculoskelet Disord. 2015;16:111.
   PubMed Web of Science ®Google Scholar
• Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 2007;56:4174–4181.
   PubMed Web of Science ®Google Scholar
• Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159:72–83.
   PubMed Web of Science ®Google Scholar
• Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974–980.
   PubMed Web of Science ®Google Scholar
• Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. Faseb J. 1996;10:1607–1613.
   PubMed Web of Science ®Google Scholar
• Meazza C, Travaglino P, Pignatti P, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:232–237.
   PubMed Web of Science ®Google Scholar